Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parkinson's Disease With End of Dose Wearing Off”

17 trials

Showing 17 of 17 results

Testing effectiveness (Phase 2)Study completedNCT00237263
What this trial is testing

An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States

Who this might be right for
Parkinson's Disease
Novartis 285
Large-scale testing (Phase 3)Study completedNCT00199407
What this trial is testing

Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Who this might be right for
Parkinson's Disease
Kyowa Kirin, Inc. 230
Testing effectiveness (Phase 2)Study completedNCT00165789
What this trial is testing

Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Who this might be right for
Parkinson's Disease
Eisai Inc. 75
Testing effectiveness (Phase 2)Study completedNCT00456586
What this trial is testing

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

Who this might be right for
Parkinson's Disease
Kyowa Kirin, Inc. 180
Post-approval studies (Phase 4)WithdrawnNCT00601978
What this trial is testing

Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off

Who this might be right for
Parkinson's Disease
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Ended earlyNCT00199381
What this trial is testing

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

Who this might be right for
Parkinson's Disease
Kyowa Kirin, Inc. 504
Testing effectiveness (Phase 2)Study completedNCT00456794
What this trial is testing

12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa

Who this might be right for
Parkinson's Disease
Kyowa Kirin, Inc. 325
Large-scale testing (Phase 3)Study completedNCT00199368
What this trial is testing

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

Who this might be right for
Parkinson's Disease
Kyowa Kirin, Inc. 1,100
Testing effectiveness (Phase 2)Study completedNCT01766258
What this trial is testing

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations

Who this might be right for
Parkinson's Disease
Orion Corporation, Orion Pharma 117
Large-scale testing (Phase 3)Ended earlyNCT02453386
What this trial is testing

Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

Who this might be right for
Idiopathic Parkinson's Disease
Biotie Therapies Inc. 449
Testing effectiveness (Phase 2)Study completedNCT03162874
What this trial is testing

Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients

Who this might be right for
Parkinson Disease
Prexton Therapeutics 157
Testing effectiveness (Phase 2)Study completedNCT02764125
What this trial is testing

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)

Who this might be right for
Parkinson's Disease
Orion Corporation, Orion Pharma 84
Large-scale testing (Phase 3)Study completedNCT00199420
What this trial is testing

Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

Who this might be right for
Parkinson's Disease
Kyowa Kirin, Inc. 580
Post-approval studies (Phase 4)Study completedNCT00219284
What this trial is testing

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

Who this might be right for
Parkinson's Disease With End of Dose Wearing Off
Novartis Pharmaceuticals 359
Testing effectiveness (Phase 2)Ended earlyNCT00427011
What this trial is testing

E2007 In Patients With Parkinson's Disease

Who this might be right for
Parkinson's Disease
Eisai Inc. 25
Large-scale testing (Phase 3)Ended earlyNCT03051607
What this trial is testing

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

Who this might be right for
Idiopathic Parkinson Disease
Biotie Therapies Inc. 66
Large-scale testing (Phase 3)Study completedNCT01283594
What this trial is testing

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

Who this might be right for
Parkinson's Disease
Biotie Therapies Inc. 420

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation